Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 19/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073359 | 0.86 | HRH1 (0.47) | HRH1CYP2D6CHRM1HTR2AKCNH2 | |
| SCHEMBL4842386 | 0.81 | HRH1 (0.76) | HRH1CYP2D6CHRM1HTR2AKCNH2 | |
| SCHEMBL4851107 | 0.77 | HRH1 (0.66) | HRH1CYP2D6CHRM1HTR2AKCNH2 | |
| SCHEMBL4847813 | 0.76 | HRH1 (1.00) | HRH1CYP2D6CHRM1HTR2AKCNH2 | |
| SCHEMBL6073265 | 0.74 | HRH1 (0.61) | HRH1CYP2D6CHRM1HTR2AKCNH2 | |
| SCHEMBL6072764 | 0.74 | HRH1 (0.65) | HRH1CYP2D6CHRM1HTR2AKCNH2 | |
| SCHEMBL4850470 | 0.74 | HRH1 (0.67) | HRH1CYP2D6CHRM1HTR2AKCNH2 | |
| SCHEMBL4850242 | 0.74 | HRH1 (0.79) | HRH1CYP2D6CHRM1HTR2AKCNH2 | |
| SCHEMBL4850678 | 0.73 | HRH1 (1.00) | HRH1CYP2D6CHRM1HTR2AKCNH2 | |
| SCHEMBL4853094 | 0.72 | HRH1 (0.60) | HRH1CYP2D6CHRM1HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393865-B2 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-07-01 | — | — | US | claimed |
| US-20060014797-A1 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-7393865-B2 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| WO-2006019497-A2 | SLEEP-INDUCING COMPOUNDS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014797-A1 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014797-A1 | Sleep inducing compounds and methods relating thereto | CHRM1, CNR1, HRH3 | HRH1 11/4885CYP2D6 83/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.